Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Brimonidine Tartrate Ophthalmic Solution, 0.2%

&times

Overview

What is Brimonidine Tartrate Ophthalmic Solution, 0.2%?

Bromonidine Tartrate Ophthalmic Solution, 0.02% is a relatively selective alpha-2 adrenergic agonist for ophthalmic use. In solution, Bromonidine Tartrate Ophthalmic Solution, 0.02% has a clear, greenish-yellow color. It has an osmolarity of 280-330 mOsmol/kg and a pH of 5.6-6.6. The structural formula is

C11H10BrN5 C4H6O6 Mol. Wt. 442.24 (as the tartrate salt) Chemical Name: 5-bromo-6-(2-imidazolidinylideneamino) quinoxaline L-tartrate, CAS Number 59803-98-4



What does Brimonidine Tartrate Ophthalmic Solution, 0.2% look like?



What are the available doses of Brimonidine Tartrate Ophthalmic Solution, 0.2%?

Sorry No records found.

What should I talk to my health care provider before I take Brimonidine Tartrate Ophthalmic Solution, 0.2%?

Sorry No records found

How should I use Brimonidine Tartrate Ophthalmic Solution, 0.2%?

Brimonidine Tartrate Ophthalmic Solution, 0.2% is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The IOP lowering efficacy of Brimonidine Tartrate Ophthalmic Solution, 0.2% diminishes over time in some patients. This loss of effect appears with a variable time of onset in each patient and should be closely monitored.

The recommended dose is one drop of Brimonidine Tartrate Ophthalmic Solution, 0.2% in the affected eye(s) three times daily, approximately 8 hours apart.

Brimonidine Tartrate Ophthalmic Solution, 0.2% may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic product is being used, the products should be administered at least 5 minutes apart.


What interacts with Brimonidine Tartrate Ophthalmic Solution, 0.2%?

Brimonidine Tartrate Ophthalmic Solution, 0.2% is contraindicated in patients with hypersensitivity to brimonidine tartrate or any component of this medication. It is also contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy.



What are the warnings of Brimonidine Tartrate Ophthalmic Solution, 0.2%?

The management of NMS should include 1) immediate discontinuation of metoclopramide and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for which specific treatments are available. Bromocriptine and dantrolene sodium have been used in treatment of NMS, but their effectiveness have not been established (see ).

Keep out of the reach of children.

Do not use if seal on the bottle is missing or broken. Rx only.


What are the precautions of Brimonidine Tartrate Ophthalmic Solution, 0.2%?

General:

Although Brimonidine Tartrate Ophthalmic Solution, 0.2% had minimal effect on blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease.

Brimonidine Tartrate Ophthalmic Solution, 0.2% has not been studied in patients with hepatic or renal impairment; caution should be used in treating such patients.

Brimonidine Tartrate Ophthalmic Solution, 0.2% should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension or thromboangiitis obliterans.

During the studies there was a loss of effect in some patients. The IOP-lowering efficacy observed with Brimonidine Tartrate Ophthalmic Solution, 0.2% during the first month of therapy may not always reflect the long-term level of IOP reduction. Patients prescribed IOP-lowering medication should be routinely monitored for IOP.

Information for patients:

The preservative in Brimonidine Tartrate Ophthalmic Solution, 0.2%, benzalkonium chloride, may be absorbed by soft contact lenses. Patients wearing soft contact lenses should be instructed to wait at least 15 minutes after instilling Brimonidine Tartrate Ophthalmic Solution, 0.2% to insert soft contact lenses. As with other drugs in this class, Brimonidine Tartrate Ophthalmic Solution, 0.2% may cause fatigue and/or drowsiness in some patients. Patients who engage in hazardous activities should be cautioned of the potential for a decrease in mental alertness.

Drug Interactions:

Although specific drug interaction studies have not been conducted with Brimonidine Tartrate Ophthalmic Solution, 0.2%, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered. Alpha-agonists, as a class, may reduce pulse and blood pressure. Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), antihypertensives and/or cardiac glycosides is advised.

Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with Brimonidine Tartrate Ophthalmic Solution, 0.2% in humans can lead to resulting interference with the IOP lowering effect. No data on the level of circulating catecholamines after Brimonidine Tartrate Ophthalmic Solution, 0.2% are available. Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.

Carcinogenesis & Mutagenesis & Impairment of Fertility:

No compound-related carcinogenic effects were observed in either mice or rats following a 21-month and 24-month study, respectively. In these studies, dietary administration of brimonidine tartrate at doses up to 2.5 mg/kg/day in mice and 1.0 mg/kg/day in rats achieved ~77 and 118 times, respectively, the plasma drug concentration estimated in humans treated with one drop Brimonidine Tartrate Ophthalmic Solution, 0.2% into both eyes 3 times per day.

Brimonidine tartrate was not mutagenic or cytogenic in a series of in vitro and in vivo studies including the Ames test, chromosomal aberation assay in Chinese Hamster Ovary (CHO) cells, a host-mediated assay and cytogenic studies in mice, and dominant lethal assay.

Reproductive studies performed in rats with oral doses of 0.66 mg base/kg revealed no evidence of harm to the fetus due to Brimonidine Tartrate Ophthalmic Solution, 0.2%.

Pregnancy:

Teratogenic Effects:

Pregnancy Category B.

Reproductive studies performed in rats with oral doses of 0.66 mg base/kg revealed no evidence of harm to the fetus due to Brimonidine Tartrate Ophthalmic Solution, 0.2%. Dosing at this level produced 100 times the plasma drug concentration level seen in humans following multiple ophthalmic doses.

There are no adequate and well-controlled studies in pregnant women. In animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent. Brimonidine Tartrate Ophthalmic Solution, 0.2% should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.

Nursing Mothers:

It is not known whether this drug is excreted in human milk; in animal studies brimonidine tartrate was excreted in breast milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use:

In a well-controlled clinical study conducted in pediatric glaucoma patients (ages 2 to 7 years) the most commonly observed adverse events with Brimonidine Tartrate Ophthalmic Solution, 0.2% dosed three times daily were somnolence (50% - 83% in patients ages 2 to 6 years) and decreased alertness. In pediatric patients 7 years of age or older (>20kg), somnolence appears to occur less frequently (25%). The most commonly observed adverse event was somnolence. Approximately 16% of patients on brimonidine tartrate ophthalmic solution discontinued from the study due to somnolence.

The safety and effectiveness of Brimonidine Tartrate Ophthalmic Solution, 0.2% have not been studied in pediatric patients below the age of 2 years. Brimonidine Tartrate Ophthalmic Solution, 0.2% is not recommended for use in pediatric patients under the age of 2 years. (Also refer to Adverse Reactions section).

Geriatric Use:

No overall differences in safety or effectiveness have been observed between elderly and other adult patients.


What are the side effects of Brimonidine Tartrate Ophthalmic Solution, 0.2%?

Adverse events occurring in approximately 10-30% of the subjects, in descending order of incidence, included oral dryness, ocular hyperemia, burning and stinging, headache, blurring, foreign body sensation, fatigue/drowsiness, conjunctival follicles, ocular allergic reactions, and ocular pruritus.

Events occurring in approximately 3-9% of the subjects, in descending order included corneal staining/erosion, photophobia, eyelid erythema, ocular ache/pain, ocular dryness, tearing, upper respiratory symptoms, eyelid edema, conjunctival edema, dizziness, blepharitis, ocular irritation, gastrointestinal symptoms, asthenia, conjunctival blanching, abnormal vision and muscular pain.

The following adverse reactions were reported in less than 3% of the patients: lid crusting, conjunctival hemorrhage, abnormal taste, insomnia, conjunctival discharge, depression, hypertension, anxiety, palpitations/arrhythmias, nasal dryness and syncope. The following events have been identified during post-marketing use of Brimonidine Tartrate Ophthalmic Solution, 0.2% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible casual connection to Brimonidine Tartrate Ophthalmic Solution, 0.2%, or a combination of these factors, include: bradycardia; hypotension; iritis; miosis; skin reactions (including erythema, eyelid pruritis, rash, and vasodilation); and tachycardia. Apnea, bradycardia, hypotension, hypothermia, hypotonia, and somnolence have been reported in infants receiving Brimonidine Tartrate Ophthalmic Solution, 0.2%.


What should I look out for while using Brimonidine Tartrate Ophthalmic Solution, 0.2%?

Brimonidine Tartrate Ophthalmic Solution, 0.2% is contraindicated in patients with hypersensitivity to brimonidine tartrate or any component of this medication. It is also contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy.

Keep out of the reach of children.

Do not use if seal on the bottle is missing or broken. Rx only.


What might happen if I take too much Brimonidine Tartrate Ophthalmic Solution, 0.2%?

No information is available on overdosage in humans. Treatment of an overdose includes supportive and symptomatic therapy. A patent airway should be maintained.


How should I store and handle Brimonidine Tartrate Ophthalmic Solution, 0.2%?

As with other potentially toxic anticancer agents, care should be exercised in the handling and preparation of infusion solutions prepared from oxaliplatin. The use of gloves is recommended. If a solution of oxaliplatin contacts the skin, wash the skin immediately and thoroughly with soap and water. If oxaliplatin contacts the mucous membranes, flush thoroughly with water.Procedures for the handling and disposal of anticancer drugs should be considered. Several guidelines on the subject have been published . There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.As with other potentially toxic anticancer agents, care should be exercised in the handling and preparation of infusion solutions prepared from oxaliplatin. The use of gloves is recommended. If a solution of oxaliplatin contacts the skin, wash the skin immediately and thoroughly with soap and water. If oxaliplatin contacts the mucous membranes, flush thoroughly with water.Procedures for the handling and disposal of anticancer drugs should be considered. Several guidelines on the subject have been published . There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.5mL in 1 BOTTLE, 1 dropper (69367-109-03)10mL in 1 BOTTLE, 1 dropper (69367-109-04)15mL in 1 BOTTLE, 1 dropper (69367-109-05)Manufactured by:Indoco Remedies Limited,L-32, 33, 34 Verna Industrial Area,Verna, Gao 403722, IndiaDistributed by:Westminster Pharmaceuticals, LLCOlive Branch, MS 386545mL in 1 BOTTLE, 1 dropper (69367-109-03)10mL in 1 BOTTLE, 1 dropper (69367-109-04)15mL in 1 BOTTLE, 1 dropper (69367-109-05)Manufactured by:Indoco Remedies Limited,L-32, 33, 34 Verna Industrial Area,Verna, Gao 403722, IndiaDistributed by:Westminster Pharmaceuticals, LLCOlive Branch, MS 386545mL in 1 BOTTLE, 1 dropper (69367-109-03)10mL in 1 BOTTLE, 1 dropper (69367-109-04)15mL in 1 BOTTLE, 1 dropper (69367-109-05)Manufactured by:Indoco Remedies Limited,L-32, 33, 34 Verna Industrial Area,Verna, Gao 403722, IndiaDistributed by:Westminster Pharmaceuticals, LLCOlive Branch, MS 386545mL in 1 BOTTLE, 1 dropper (69367-109-03)10mL in 1 BOTTLE, 1 dropper (69367-109-04)15mL in 1 BOTTLE, 1 dropper (69367-109-05)Manufactured by:Indoco Remedies Limited,L-32, 33, 34 Verna Industrial Area,Verna, Gao 403722, IndiaDistributed by:Westminster Pharmaceuticals, LLCOlive Branch, MS 386545mL in 1 BOTTLE, 1 dropper (69367-109-03)10mL in 1 BOTTLE, 1 dropper (69367-109-04)15mL in 1 BOTTLE, 1 dropper (69367-109-05)Manufactured by:Indoco Remedies Limited,L-32, 33, 34 Verna Industrial Area,Verna, Gao 403722, IndiaDistributed by:Westminster Pharmaceuticals, LLCOlive Branch, MS 386545mL in 1 BOTTLE, 1 dropper (69367-109-03)10mL in 1 BOTTLE, 1 dropper (69367-109-04)15mL in 1 BOTTLE, 1 dropper (69367-109-05)Manufactured by:Indoco Remedies Limited,L-32, 33, 34 Verna Industrial Area,Verna, Gao 403722, IndiaDistributed by:Westminster Pharmaceuticals, LLCOlive Branch, MS 386545mL in 1 BOTTLE, 1 dropper (69367-109-03)10mL in 1 BOTTLE, 1 dropper (69367-109-04)15mL in 1 BOTTLE, 1 dropper (69367-109-05)Manufactured by:Indoco Remedies Limited,L-32, 33, 34 Verna Industrial Area,Verna, Gao 403722, IndiaDistributed by:Westminster Pharmaceuticals, LLCOlive Branch, MS 386545mL in 1 BOTTLE, 1 dropper (69367-109-03)10mL in 1 BOTTLE, 1 dropper (69367-109-04)15mL in 1 BOTTLE, 1 dropper (69367-109-05)Manufactured by:Indoco Remedies Limited,L-32, 33, 34 Verna Industrial Area,Verna, Gao 403722, IndiaDistributed by:Westminster Pharmaceuticals, LLCOlive Branch, MS 386545mL in 1 BOTTLE, 1 dropper (69367-109-03)10mL in 1 BOTTLE, 1 dropper (69367-109-04)15mL in 1 BOTTLE, 1 dropper (69367-109-05)Manufactured by:Indoco Remedies Limited,L-32, 33, 34 Verna Industrial Area,Verna, Gao 403722, IndiaDistributed by:Westminster Pharmaceuticals, LLCOlive Branch, MS 386545mL in 1 BOTTLE, 1 dropper (69367-109-03)10mL in 1 BOTTLE, 1 dropper (69367-109-04)15mL in 1 BOTTLE, 1 dropper (69367-109-05)Manufactured by:Indoco Remedies Limited,L-32, 33, 34 Verna Industrial Area,Verna, Gao 403722, IndiaDistributed by:Westminster Pharmaceuticals, LLCOlive Branch, MS 38654


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Mechanism of Action:

Brimonidine Tartrate Ophthalmic Solution, 0.2% is an alpha adrenergic receptor agonist. It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.

Pharmacokinetics:

After ocular administration of a 0.2% solution, plasma concentrations peaked within 1 to 4 hours and declined with a systemic half-life of approximately 3 hours. In humans, systemic metabolism of brimonidine is extensive. It is metabolized primarily by the liver. Urinary excretion is the major route of elimination of the drug and its metabolites. Approximately 87% of an orally- administered radioactive dose was eliminated within 120 hours, with 74% found in the urine.

Clinical Evaluations:

Elevated IOP presents a major risk factor in glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss. Brimonidine tartrate has the action of lowering intraocular pressure with minimal effect on cardiovascular and pulmonary parameters.

In comparative clinical studies with timolol 0.5%, lasting up to one year, the IOP lowering effect of Brimonidine Tartrate Ophthalmic Solution, 0.2% was approximately 4 - 6 mmHg compared with approximately 6 mmHg for timolol. In these studies, both patient groups were dosed BID; however, due to the duration of action of Brimonidine Tartrate Ophthalmic Solution, 0.2%; it is recommended that Brimonidine Tartrate Ophthalmic Solution, 0.2% be dosed TID. Eight percent of subjects were discontinued from studies due to inadequately controlled intraocular pressure, which in 30% of these patients occurred during the first month of therapy. Approximately 20% were discontinued due to adverse experiences.

Non-Clinical Toxicology
Brimonidine Tartrate Ophthalmic Solution, 0.2% is contraindicated in patients with hypersensitivity to brimonidine tartrate or any component of this medication. It is also contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy.

Keep out of the reach of children.

Do not use if seal on the bottle is missing or broken. Rx only.

The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.

The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxidase inhibitors.

Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).

Gastroparesis (gastric stasis) may be responsible for poor diabetic control in some patients. Exogenously administered insulin may begin to act before food has left the stomach and lead to hypoglycemia. Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment.

General:

Although Brimonidine Tartrate Ophthalmic Solution, 0.2% had minimal effect on blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease.

Brimonidine Tartrate Ophthalmic Solution, 0.2% has not been studied in patients with hepatic or renal impairment; caution should be used in treating such patients.

Brimonidine Tartrate Ophthalmic Solution, 0.2% should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension or thromboangiitis obliterans.

During the studies there was a loss of effect in some patients. The IOP-lowering efficacy observed with Brimonidine Tartrate Ophthalmic Solution, 0.2% during the first month of therapy may not always reflect the long-term level of IOP reduction. Patients prescribed IOP-lowering medication should be routinely monitored for IOP.

Information for patients:

The preservative in Brimonidine Tartrate Ophthalmic Solution, 0.2%, benzalkonium chloride, may be absorbed by soft contact lenses. Patients wearing soft contact lenses should be instructed to wait at least 15 minutes after instilling Brimonidine Tartrate Ophthalmic Solution, 0.2% to insert soft contact lenses. As with other drugs in this class, Brimonidine Tartrate Ophthalmic Solution, 0.2% may cause fatigue and/or drowsiness in some patients. Patients who engage in hazardous activities should be cautioned of the potential for a decrease in mental alertness.

Drug Interactions:

Although specific drug interaction studies have not been conducted with Brimonidine Tartrate Ophthalmic Solution, 0.2%, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered. Alpha-agonists, as a class, may reduce pulse and blood pressure. Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), antihypertensives and/or cardiac glycosides is advised.

Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with Brimonidine Tartrate Ophthalmic Solution, 0.2% in humans can lead to resulting interference with the IOP lowering effect. No data on the level of circulating catecholamines after Brimonidine Tartrate Ophthalmic Solution, 0.2% are available. Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.

Carcinogenesis & Mutagenesis & Impairment of Fertility:

No compound-related carcinogenic effects were observed in either mice or rats following a 21-month and 24-month study, respectively. In these studies, dietary administration of brimonidine tartrate at doses up to 2.5 mg/kg/day in mice and 1.0 mg/kg/day in rats achieved ~77 and 118 times, respectively, the plasma drug concentration estimated in humans treated with one drop Brimonidine Tartrate Ophthalmic Solution, 0.2% into both eyes 3 times per day.

Brimonidine tartrate was not mutagenic or cytogenic in a series of in vitro and in vivo studies including the Ames test, chromosomal aberation assay in Chinese Hamster Ovary (CHO) cells, a host-mediated assay and cytogenic studies in mice, and dominant lethal assay.

Reproductive studies performed in rats with oral doses of 0.66 mg base/kg revealed no evidence of harm to the fetus due to Brimonidine Tartrate Ophthalmic Solution, 0.2%.

Pregnancy:

Teratogenic Effects:

Pregnancy Category B.

Reproductive studies performed in rats with oral doses of 0.66 mg base/kg revealed no evidence of harm to the fetus due to Brimonidine Tartrate Ophthalmic Solution, 0.2%. Dosing at this level produced 100 times the plasma drug concentration level seen in humans following multiple ophthalmic doses.

There are no adequate and well-controlled studies in pregnant women. In animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent. Brimonidine Tartrate Ophthalmic Solution, 0.2% should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.

Nursing Mothers:

It is not known whether this drug is excreted in human milk; in animal studies brimonidine tartrate was excreted in breast milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use:

In a well-controlled clinical study conducted in pediatric glaucoma patients (ages 2 to 7 years) the most commonly observed adverse events with Brimonidine Tartrate Ophthalmic Solution, 0.2% dosed three times daily were somnolence (50% - 83% in patients ages 2 to 6 years) and decreased alertness. In pediatric patients 7 years of age or older (>20kg), somnolence appears to occur less frequently (25%). The most commonly observed adverse event was somnolence. Approximately 16% of patients on brimonidine tartrate ophthalmic solution discontinued from the study due to somnolence.

The safety and effectiveness of Brimonidine Tartrate Ophthalmic Solution, 0.2% have not been studied in pediatric patients below the age of 2 years. Brimonidine Tartrate Ophthalmic Solution, 0.2% is not recommended for use in pediatric patients under the age of 2 years. (Also refer to Adverse Reactions section).

Geriatric Use:

No overall differences in safety or effectiveness have been observed between elderly and other adult patients.

Adverse events occurring in approximately 10-30% of the subjects, in descending order of incidence, included oral dryness, ocular hyperemia, burning and stinging, headache, blurring, foreign body sensation, fatigue/drowsiness, conjunctival follicles, ocular allergic reactions, and ocular pruritus.

Events occurring in approximately 3-9% of the subjects, in descending order included corneal staining/erosion, photophobia, eyelid erythema, ocular ache/pain, ocular dryness, tearing, upper respiratory symptoms, eyelid edema, conjunctival edema, dizziness, blepharitis, ocular irritation, gastrointestinal symptoms, asthenia, conjunctival blanching, abnormal vision and muscular pain.

The following adverse reactions were reported in less than 3% of the patients: lid crusting, conjunctival hemorrhage, abnormal taste, insomnia, conjunctival discharge, depression, hypertension, anxiety, palpitations/arrhythmias, nasal dryness and syncope. The following events have been identified during post-marketing use of Brimonidine Tartrate Ophthalmic Solution, 0.2% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible casual connection to Brimonidine Tartrate Ophthalmic Solution, 0.2%, or a combination of these factors, include: bradycardia; hypotension; iritis; miosis; skin reactions (including erythema, eyelid pruritis, rash, and vasodilation); and tachycardia. Apnea, bradycardia, hypotension, hypothermia, hypotonia, and somnolence have been reported in infants receiving Brimonidine Tartrate Ophthalmic Solution, 0.2%.

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).